Answers are grounded in this paper and cite their sources.
To the Editor: We would like to inform the readers of the variability of response of very-early-onset inflammatory bowel disease–associated heterozygous signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) mutations to ruxolitinib. Heterozygous STAT1-GOF mutations typically present as chronic mucocutaneous candidiasis, but can also affect the gastrointestinal tract resulting in failure to thrive (FTT) and enteropathy (1–3). JAK inhibitor therapy has been reported to improve symptoms in patients with STAT1 GOF although with variable outcomes (4–6). A 7-month-old girl born full-term to non-consanguineous Moroccan parents presented with a chronic diaper rash and FTT and was admitted for diarrhea and dehydration. She had developed oral thrush and a diaper rash at 2 weeks of age, an Escherichia coli labial abscess complicated by a rectolabial fistula at 5 weeks, food protein–induced enterocolitis syndrome at 3 months, and chronic diarrhea and FTT. On physical examination her perianal area had a deep ulceration, erythema, and a fissure (Fig. 1 A and B). Laboratory findings revealed anemia, thrombocytopenia, and normal lymphocyte subsets, immunoglobulin levels, proliferative response to mitogens and Candida, and neutrophil oxidative burst assay. Whole exome sequencing identified a novel, de novo heterozygous variant in STAT1 (c.1627T >C, p.Cys543Arg) (Supplemental Fig. A, Supplemental Digital Content, https://links.lww.com/MPG/B887) in the STAT1 linker domain identified as a GOF mutation based on an interferon-gamma activation sequence (GAS) reporter assay (Supplemental Fig. B, Supplemental Digital Content, https://links.lww.com/MPG/B887). Upper endoscopy and colonoscopy revealed villus atrophy throughout the duodenum with mild intraepithelial lymphocytosis and expansion of the lamina propria by a chronic inflammatory infiltrate composed of lymphocytes, plasma cells, and scattered eosinophils.FIGURE 1: A, Erythematous plaques involving the gluteal fold consistent with cutaneous candidiasis (B) and right labial abscess and perianal fistula prior to ruxolitinib treatment. C, Improved diaper candidiasis 5 weeks after initiation of ruxolitinib. Written consent to present patient images obtained by patient's parents.She was started on ruxolitinib, a JAK1/2 inhibitor, at 1 year of age on a dose of 5 mg/m2/dose BID and titrated up to 15 mg/m2/dose BID by 4 weeks. In the 12-month period after starting ruxolitinib, her cutaneous candidiasis (Fig. 1C) and autoimmune cytopenias improved, and she briefly achieved enteral sufficiency. Unfortunately, her diarrhea and dependence on total parenteral nutrition returned. Further increases in her dose were deferred due to oral herpes simplex virus, a known risk of ruxolitinib (5). Repeat upper endoscopy and colonoscopy 6 months after starting ruxolitinib demonstrated total villus atrophy, mild patchy intraepithelial lymphocytosis, and an expanded lamina propria chronic inflammatory infiltrate. Our patient's mucosal histology likely mimics those of patients with STAT1 GOF and IPEX-like syndrome who suffer from severe enteropathy and have villus blunting or atrophy and lymphocytic enteritis (7). Thus, ruxolitinib did not appear to result in any improvement, and her findings were stable if not worse from prior to the start of this agent. The reason for her partial response to ruxolitinib remains unclear and may be due to poor gastrointestinal absorption, insufficient dose (6), or failure of ruxolitinib to fully restore immune function in the long-term (4). Although the most promising agent for STAT1 GOF is JAK inhibitor therapy with ruxolitinib, there are gaps in understanding its variable response in patients with gastrointestinal manifestations of STAT1 GOF.
No takes yet. Share an insight, caveat, or question.
Acker et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: